Advertisement
Video

Terri E. Weaver, PhD, RN, on Efficacy of Solriamfetol for Treating Symptoms of Obstructive Sleep Apnea

01/14/2021

In this video, Terri E. Weaver, PhD, RN, talks about the effectiveness of solriamfetol in improving daily functioning, reducing daytime sleepiness, and enhancing work productivity.

Additional Resource:

Terri E. Weaver, PhD, RN, is dean and professor in the Department of Behavioral Nursing Science in the College of Nursing and professor in the Division of Pulmonary, Critical Care, Sleep, and Allergy in the Department of Medicine in the College of Medicine at the University of Illinois at Chicago.

TRANSCRIPT:

My name is Terri Weaver, I am Dean and professor at the University of Illinois Chicago College of Nursing.

This was a study to look at the effectiveness as opposed to the efficacy of solriamfetol with particular outcomes of daily functioning, daytime sleepiness, and also work productivity, along with perception of change by the patient and also the clinician.

It is approved for daytime sleepiness and patients with obstructive sleep apnea. It’s also approved for the treatment of sleepiness and narcolepsy. It is approved for 3 doses—75 mg, 150 mg, and 300 mg.

The findings showed that when this was evaluated, especially with a withdrawal phase that included a placebo, that the efficacy of solriamfetol was maintained long term, 40 weeks out.

So, the initial studies with clinical trial that was done to prove efficacy of solriamfetol showed that it was efficacious for daytime sleepiness, daily functioning, and work productivity. This study showed that efficacy was maintained long term, which was clinical effectiveness. And so, it has both efficacy and effectiveness

A component of the study was a withdrawal phase where individuals who were on doses that treated their sleepiness, when you withdrew that, in fact, they were still able to see the benefit in several outcomes that were the case with regard to the initial evaluation of the agent and that those who were placed on placebo during that time had a decline.

Thank you for the opportunity to share our work, greatly appreciate it.

Related Content

Public Health
Public Health
Jaspal Singh, MD, MHA, MHS, on How I Practice Now: Transitioning Pulmonary and Critical Care Patients to Virtual Visits
12/27/2020
In this video, Pulmonology Consultant Advisory Board Member Jaspal Singh, MD, MHA, MHS, explains how the COVID-19 pandemic is causing him and his colleagues to rethink how immediate care to the bedside is...
12/27/2020
Gastroenterology
B Abraham
Gastroenterology
Bincy Abrahams, MD, on Treating IBD Without the mAbs and the JAKs
09/25/2020
In this 3-minute video, Dr Abraham reviews her discussion of how to treat IBD without biologics, Janus kinase inhibitors, and other new therapeutic agents.
09/25/2020
Stress and Burnout
Niederman
Stress and Burnout
Michael Niederman, MD, on How COVID-19 Has Changed the Inpatient Experience
08/14/2016
In part 2 of 3 of this video series, Pulmonology Consultant Advisory Board Member Michael Niederman, MD, discusses the long-lasting impacts that the COVID-19 pandemic will have on the inpatient experience,...
08/14/2016
Mental Health
Mental Health
Reza Hosseini Ghomi, MD, MS on Detecting and Tracking Depression Through Voice Samples
05/26/2020
In this video, researcher and neuropsychiatrist Reza Hosseini Ghomi, MD, MSE, shares details about a study that suggests automatic language processing may be able to play a role in detecting and tracking...
05/26/2020
Patient-Provider Relationship
Patient-Provider Relationship
James Matera, MD, on What Questions do Patients With Chronic Kidney Disease Ask?
11/18/2019
In this video, James Matera, MD, talks about the critical questions patients have about CKD, the impact of CKD on comorbid conditions and the need to limit risk, and more.
11/18/2019